Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.
about
Bortezomib for the treatment of mantle cell lymphoma: an updateThe role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Management of mantle cell lymphoma in the elderly patientMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsMantle cell lymphoma: observation to transplantationCurrent and emerging therapies in mantle cell lymphoma.Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project DatabaIn chordoma, metastasis, recurrences, Ki-67 index, and a matrix-poor phenotype are associated with patients' shorter overall survival.Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS groupBortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science studyNotch-1 and Ki-67 receptor as predictors for the recurrence and prognosis of Kimura's disease.Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting.Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphomaEndoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvementLong-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma GroupKi-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysisVcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patientsThe impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.Non-Hodgkin's lymphomas, version 4.2014.Prognostic relevance of the Ki-67 proliferation index in patients with mantle cell lymphoma.Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results.Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trialWhat is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?Molecular outcome prediction in mantle cell lymphoma.Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma.Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2008.Mantle cell lymphoma: state-of-the-art management and future perspective.Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?Advances in the molecular morphology of hematopathology.Temsirolimus for the treatment of mantle cell lymphoma.Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network.Lenalidomide in lymphomas and chronic lymphocytic leukemia.Indolent mantle cell lymphoma.Management of mantle cell lymphoma in the elderly: current and potential strategies.Current regimens and novel agents for mantle cell lymphoma.The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.
P2860
Q26738940-C71F2CFE-C1AF-42AE-B183-9B1129DF808CQ26772907-91616E91-ADE9-4A06-9FB4-2D2CB29C219BQ26999395-0ED48E34-D516-4D3A-822F-5A3FA244BC9EQ28075606-0FC0B858-2AD8-45AB-A4A3-622216AC605FQ28256317-BE05F55D-79CC-4493-A5D9-7CD56F515ACAQ30456545-D8350600-8D64-4DA0-8576-5B531C592606Q30649483-34FD85A9-D458-416E-BE33-F9AD3A7321DBQ33275755-33AC8811-07D6-42BF-8EB0-48F53DC2F3F5Q33388563-C8461B93-5585-4C91-A3B9-A559D542CFF9Q33394873-23D82E85-D4D7-426A-90B7-D992E7BE2205Q33572807-4164951E-CD61-402F-B1A2-FE0CC6B4C896Q33802961-2FF8FF83-38D5-4D61-87C5-B1035ACE577DQ34037828-293851C1-F065-4EB6-81BA-CB09C3D1959EQ34095625-30427E6A-3029-463C-A4A9-864320BC2F49Q34135450-110B3683-A524-413E-869D-F0C0CA68F650Q34183167-DAD9E9A2-BB90-4754-86F6-A3792788EA59Q34594224-D18E2194-3767-49E7-AE0E-F524B620B8C0Q35111804-F9CD67A0-669F-4518-BE61-CE45498D65E5Q35285011-7E20D87E-9B26-496E-8EC1-79B23818A20DQ36162589-D41CCFF6-5EAE-40E1-AD09-DD7235052DEFQ36216258-9EF94135-76B0-4D09-B312-DEAE5A54EBADQ36820885-D8456EF3-4A16-40D8-85DB-B91D27F2B20FQ37062711-E75298EB-9873-4A96-8219-3401C0197747Q37195045-BB2C1214-E754-4F74-8363-8F36886B2344Q37269566-D205B6EA-6A12-4148-9266-7FA1FD982981Q37271814-1BFBA062-301E-449E-BC22-C1824154E205Q37401338-8C48D586-818D-4EC6-A7A0-B40FF9F4A29BQ37482527-5376F188-54F4-451C-9E07-1B51509E6FE2Q37534534-D68DD57C-7911-409D-908E-34841C09FAD0Q37577541-BC247C07-2630-4281-A401-0DA6A61BA4E1Q37622873-3D79EBAF-C374-4EB1-A2A2-73A39434C037Q37728866-F8EA6D4C-E1A8-431D-B6F7-CF2EE2F69CA5Q37756388-858D5B0F-AE85-4E75-89D7-3DDB261BC833Q37810084-8D1C90C8-9BEB-42E2-B2D1-AB2EDBA04F4EQ38047385-265FF006-6108-4E26-B145-FC2C133FEE3EQ38077277-1A7E596C-5276-4734-AEA1-A046E27BA6FEQ38127446-206F7F8F-F0CC-4635-B1E4-583D94B70E98Q38157682-9EFB6134-A9CC-4B6D-B09B-806D9BCC6F16Q38224186-84398B9D-BB33-47EA-8F3A-5CFFE8B1DC9AQ38230693-657AAA36-918F-4591-8ED5-5CCAA5B52BE3
P2860
Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.
@ast
Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.
@en
Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.
@nl
type
label
Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.
@ast
Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.
@en
Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.
@nl
prefLabel
Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.
@ast
Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.
@en
Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.
@nl
P2093
P1433
P1476
Ki-67 predicts outcome in adva ...... ow Grade Lymphoma Study Group.
@en
P2093
European Mantle Cell Lymphoma Network and the German Low Grade Lymphoma Study Group
Eva Hoster
German Ott
Heinz Wolfram Bernd
Martin Dreyling
Martin Leo Hansmann
Michael Unterhalt
Olaf Determann
Thomas E F Barth
Wolfgang Hiddemann
P304
P356
10.1182/BLOOD-2007-10-117010
P407
P577
2007-12-12T00:00:00Z